News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,894 Results
Type
Article (14216)
Company Profile (104)
Press Release (261574)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (90234)
Career Advice (469)
Deals (15730)
Drug Delivery (67)
Drug Development (38032)
Employer Resources (49)
FDA (6877)
Job Trends (6368)
News (154779)
Policy (14399)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (466)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23860)
ALS (36)
Alzheimer's disease (399)
Antibody-drug conjugate (ADC) (38)
Approvals (6908)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (153)
Best Places to Work (4519)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (41)
Bladder cancer (26)
Brain cancer (17)
Breast cancer (79)
Cancer (653)
Cardiovascular disease (74)
Career advice (411)
Career pathing (11)
CAR-T (22)
Cell therapy (88)
Cervical cancer (4)
Clinical research (31986)
Collaboration (356)
Compensation (167)
Complete response letters (17)
COVID-19 (773)
CRISPR (20)
C-suite (122)
Cystic fibrosis (38)
Data (671)
Denatured (15)
Depression (9)
Diabetes (85)
Diagnostics (1425)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (65)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (33087)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (39123)
Executive appointments (388)
FDA (7322)
Featured Employer (21)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (216)
Gene editing (38)
Generative AI (9)
Gene therapy (103)
GLP-1 (352)
Government (1352)
Grass and pollen (2)
Guidances (18)
Healthcare (3998)
Huntington's disease (4)
IgA nephropathy (13)
Immunology and inflammation (35)
Indications (13)
Infectious disease (811)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (6043)
IRA (29)
Job creations (2071)
Job search strategy (377)
Kidney cancer (6)
Labor market (11)
Layoffs (184)
Leadership (3)
Legal (3475)
Liver cancer (20)
Lung cancer (88)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (155)
MASH (34)
Medical device (1965)
Medtech (1967)
Mergers & acquisitions (9897)
Metabolic disorders (268)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (583)
NextGen: Class of 2025 (1688)
Non-profit (613)
Northern California (799)
Now hiring (7)
Obesity (149)
Opinion (120)
Ovarian cancer (23)
Pain (54)
Pancreatic cancer (16)
Parkinson's disease (47)
Partnered (7)
Patents (122)
Patient recruitment (31)
Peanut (10)
People (29387)
Pharmaceutical (66)
Pharmacy benefit managers (11)
Phase I (8582)
Phase II (13599)
Phase III (11923)
Pipeline (462)
Policy (70)
Postmarket research (1415)
Preclinical (3464)
Press Release (26)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (125)
Rare diseases (173)
Real estate (2687)
Recruiting (17)
Regulatory (10410)
Reports (15)
Research institute (607)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (2)
RSV (11)
Schizophrenia (36)
Series A (36)
Series B (14)
Service/supplier (3)
Sickle cell disease (32)
Southern California (745)
Special edition (6)
Spinal muscular atrophy (78)
Sponsored (6)
Startups (1675)
State (2)
Stomach cancer (3)
Supply chain (33)
Tariffs (21)
The Weekly (30)
United States (7562)
Vaccines (164)
Venture capitalists (14)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Today (12)
Last 7 days (189)
Last 30 days (892)
Last 365 days (12441)
2025 (3594)
2024 (13203)
2023 (15024)
2022 (20628)
2021 (21184)
2020 (19937)
2019 (15503)
2018 (12270)
2017 (14445)
2016 (13615)
2015 (16045)
2014 (12866)
2013 (10956)
2012 (11711)
2011 (12272)
2010 (11152)
Location
Africa (318)
Alabama (16)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20860)
Australia (2668)
California (1865)
Canada (916)
China (244)
Colorado (72)
Connecticut (70)
Delaware (55)
Europe (40465)
Florida (344)
Georgia (39)
Idaho (11)
Illinois (203)
India (16)
Indiana (136)
Iowa (2)
Japan (91)
Kansas (57)
Kentucky (12)
Louisiana (2)
Maine (3)
Maryland (272)
Massachusetts (1563)
Michigan (30)
Minnesota (102)
Mississippi (1)
Missouri (23)
Montana (19)
Nebraska (6)
Nevada (10)
New Hampshire (6)
New Jersey (776)
New Mexico (8)
New York (508)
North Carolina (397)
North Dakota (2)
Northern California (799)
Ohio (50)
Oklahoma (4)
Oregon (16)
Pennsylvania (467)
Puerto Rico (8)
Rhode Island (10)
South America (509)
South Carolina (2)
Southern California (745)
Tennessee (35)
Texas (243)
Utah (34)
Virginia (74)
Washington D.C. (31)
Washington State (118)
Wisconsin (17)
275,894 Results for "fusion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Acquisition of Fusion Pharmaceuticals Completed
Fusion Pharmaceuticals Inc. announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement.
June 4, 2024
·
6 min read
Press Releases
Biomea Fusion Announces Leadership Transition
March 26, 2025
·
3 min read
Press Releases
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
March 24, 2025
·
2 min read
Deals
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
Fusion Pharmaceuticals Inc. announced that at a special meeting of its shareholders, held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion.
May 29, 2024
·
4 min read
Press Releases
Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System
March 26, 2025
·
3 min read
Press Releases
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
April 1, 2025
·
14 min read
Genetown
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.
February 26, 2024
·
2 min read
Press Releases
Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System
April 2, 2025
·
5 min read
Press Releases
Study Confirms Significant Clinical Benefit of Neo Medical’s Force Control Technology™ in Spinal Fusion Surgery
April 1, 2025
·
4 min read
Business
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024, and provided an update on clinical and corporate developments.
May 7, 2024
·
15 min read
1 of 27,590
Next
